{"entity":{"type":"insider","cik":"0001882909","url":"/insider/0001882909","json_url":"/insider/0001882909.json","name":"Calvin Sandra","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":27,"n_filings":19,"first":"2022-01-26","last":"2026-04-16","span_basis":"filed_date"},"name_variants":[{"name":"Calvin Sandra","source":"filing","n_filings":19,"first_seen":"2022-01-26","last_seen":"2026-04-16"}],"transactions":[{"id":5866075,"accession":"0001882909-26-000003","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001882909-26-000003","line_url":"/filing/0001882909-26-000003#line-4","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21977.0,"shares_display":"21,977","price_per_share":41.07,"price_display":"41.07","price_state":"stated","total_value":902595.39,"total_display":"902,595.39","total_whole":"902,595","shares_owned_after":42353.0,"shares_owned_after_display":"42,353","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-16","scope":"insider"},{"id":5841405,"accession":"0001882909-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001882909-26-000001","line_url":"/filing/0001882909-26-000001#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4333.0,"shares_display":"4,333","price_per_share":32.12,"price_display":"32.12","price_state":"stated","total_value":139175.96,"total_display":"139,175.96","total_whole":"139,176","shares_owned_after":49080.0,"shares_owned_after_display":"49,080","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":4606890,"accession":"0001882909-25-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001882909-25-000008","line_url":"/filing/0001882909-25-000008#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7402.0,"shares_display":"7,402","price_per_share":40.0,"price_display":"40.00","price_state":"stated","total_value":296080.0,"total_display":"296,080.00","total_whole":"296,080","shares_owned_after":38233.0,"shares_owned_after_display":"38,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-24","filed_date":"2025-12-29","scope":"insider"},{"id":4972332,"accession":"0001882909-25-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001882909-25-000006","line_url":"/filing/0001882909-25-000006#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2910.0,"shares_display":"2,910","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":104760.0,"total_display":"104,760.00","total_whole":"104,760","shares_owned_after":45635.0,"shares_owned_after_display":"45,635","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-16","scope":"insider"},{"id":4518207,"accession":"0001882909-25-000004","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001882909-25-000004","line_url":"/filing/0001882909-25-000004#line-6","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67115.0,"shares_display":"67,115","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":2416140.0,"total_display":"2,416,140.00","total_whole":"2,416,140","shares_owned_after":48545.0,"shares_owned_after_display":"48,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-04","filed_date":"2025-11-06","scope":"insider"},{"id":4466444,"accession":"0001415889-25-003822","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001415889-25-003822","line_url":"/filing/0001415889-25-003822","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54244.0,"shares_display":"54,244","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":1356100.0,"total_display":"1,356,100.00","total_whole":"1,356,100","shares_owned_after":63654.0,"shares_owned_after_display":"63,654","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-11","filed_date":"2025-02-12","scope":"insider","n_lines":5},{"id":4318169,"accession":"0001415889-25-003061","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003061","line_url":"/filing/0001415889-25-003061#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3348.0,"shares_display":"3,348","price_per_share":20.12,"price_display":"20.12","price_state":"stated","total_value":67361.76,"total_display":"67,361.76","total_whole":"67,362","shares_owned_after":63654.0,"shares_owned_after_display":"63,654","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-04","scope":"insider"},{"id":5002705,"accession":"0001415889-25-001997","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-001997","line_url":"/filing/0001415889-25-001997#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":925.0,"shares_display":"925","price_per_share":18.9408,"price_display":"18.94","price_state":"stated","total_value":17520.24,"total_display":"17,520.24","total_whole":"17,520","shares_owned_after":54002.0,"shares_owned_after_display":"54,002","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-22","filed_date":"2025-01-23","scope":"insider"},{"id":2565902,"accession":"0001415889-24-030210","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-030210","line_url":"/filing/0001415889-24-030210#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":17.2185,"price_display":"17.22","price_state":"stated","total_value":258277.5,"total_display":"258,277.50","total_whole":"258,278","shares_owned_after":54927.0,"shares_owned_after_display":"54,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-26","filed_date":"2024-12-27","scope":"insider"},{"id":3143892,"accession":"0001415889-24-027672","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-027672","line_url":"/filing/0001415889-24-027672#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12090.0,"shares_display":"12,090","price_per_share":18.3009,"price_display":"18.30","price_state":"stated","total_value":221257.881,"total_display":"221,257.88","total_whole":"221,258","shares_owned_after":54927.0,"shares_owned_after_display":"54,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-25","filed_date":"2024-11-25","scope":"insider"},{"id":2595196,"accession":"0001415889-24-002279","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-002279","line_url":"/filing/0001415889-24-002279#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2820.0,"shares_display":"2,820","price_per_share":8.5312,"price_display":"8.53","price_state":"stated","total_value":24057.984,"total_display":"24,057.98","total_whole":"24,058","shares_owned_after":52017.0,"shares_owned_after_display":"52,017","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-01","filed_date":"2024-02-02","scope":"insider"},{"id":2255187,"accession":"0001415889-24-001796","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-001796","line_url":"/filing/0001415889-24-001796#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF ACCOUNTING OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":910.0,"shares_display":"910","price_per_share":9.0684,"price_display":"9.07","price_state":"stated","total_value":8252.244,"total_display":"8,252.24","total_whole":"8,252","shares_owned_after":41337.0,"shares_owned_after_display":"41,337","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-23","filed_date":"2024-01-25","scope":"insider"},{"id":8022291,"accession":"0001209191-23-028993","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-028993","line_url":"/filing/0001209191-23-028993#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":122.0,"shares_display":"122","price_per_share":16.12,"price_display":"16.12","price_state":"stated","total_value":1966.64,"total_display":"1,966.64","total_whole":"1,967","shares_owned_after":42247.0,"shares_owned_after_display":"42,247","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-11","filed_date":"2023-05-12","scope":"insider"},{"id":8022289,"accession":"0001209191-23-028993","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-028993","line_url":"/filing/0001209191-23-028993#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":436.0,"shares_display":"436","price_per_share":16.59,"price_display":"16.59","price_state":"stated","total_value":7233.24,"total_display":"7,233.24","total_whole":"7,233","shares_owned_after":42369.0,"shares_owned_after_display":"42,369","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-10","filed_date":"2023-05-12","scope":"insider"},{"id":8287658,"accession":"0001209191-23-006413","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-006413","line_url":"/filing/0001209191-23-006413#line-3","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":360.0,"shares_display":"360","price_per_share":22.42,"price_display":"22.42","price_state":"stated","total_value":8071.2,"total_display":"8,071.20","total_whole":"8,071","shares_owned_after":42805.0,"shares_owned_after_display":"42,805","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-02","filed_date":"2023-02-02","scope":"insider"},{"id":8287654,"accession":"0001209191-23-006413","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-006413","line_url":"/filing/0001209191-23-006413#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1671.0,"shares_display":"1,671","price_per_share":21.752,"price_display":"21.75","price_state":"stated","total_value":36347.592,"total_display":"36,347.59","total_whole":"36,348","shares_owned_after":43165.0,"shares_owned_after_display":"43,165","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider"},{"id":7809417,"accession":"0001209191-23-005037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-005037","line_url":"/filing/0001209191-23-005037#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":192.0,"shares_display":"192","price_per_share":21.63,"price_display":"21.63","price_state":"stated","total_value":4152.96,"total_display":"4,152.96","total_whole":"4,153","shares_owned_after":34836.0,"shares_owned_after_display":"34,836","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-25","filed_date":"2023-01-26","scope":"insider"},{"id":7809413,"accession":"0001209191-23-005037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005037","line_url":"/filing/0001209191-23-005037#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":905.0,"shares_display":"905","price_per_share":21.9044,"price_display":"21.90","price_state":"stated","total_value":19823.482,"total_display":"19,823.48","total_whole":"19,823","shares_owned_after":35028.0,"shares_owned_after_display":"35,028","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-24","filed_date":"2023-01-26","scope":"insider"},{"id":6729794,"accession":"0001209191-22-050038","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-050038","line_url":"/filing/0001209191-22-050038#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":349.0,"shares_display":"349","price_per_share":28.0,"price_display":"28.00","price_state":"stated","total_value":9772.0,"total_display":"9,772.00","total_whole":"9,772","shares_owned_after":35933.0,"shares_owned_after_display":"35,933","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-13","filed_date":"2022-09-15","scope":"insider"},{"id":6251203,"accession":"0001209191-22-028706","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-028706","line_url":"/filing/0001209191-22-028706#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":445.0,"shares_display":"445","price_per_share":21.9235,"price_display":"21.92","price_state":"stated","total_value":9755.9575,"total_display":"9,755.96","total_whole":"9,756","shares_owned_after":35733.0,"shares_owned_after_display":"35,733","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-11","filed_date":"2022-05-12","scope":"insider"},{"id":6251199,"accession":"0001209191-22-028706","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-028706","line_url":"/filing/0001209191-22-028706#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (SVP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":436.0,"shares_display":"436","price_per_share":21.51,"price_display":"21.51","price_state":"stated","total_value":9378.36,"total_display":"9,378.36","total_whole":"9,378","shares_owned_after":36178.0,"shares_owned_after_display":"36,178","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-10","filed_date":"2022-05-12","scope":"insider"},{"id":6142781,"accession":"0001209191-22-006372","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-006372","line_url":"/filing/0001209191-22-006372#line-2","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (VP, Corp Controller and CAO)","role_mark":"O","role_mark_label":"Officer (VP, Corp Controller and CAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Corp Controller and CAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":798.0,"shares_display":"798","price_per_share":26.5059,"price_display":"26.51","price_state":"stated","total_value":21151.7082,"total_display":"21,151.71","total_whole":"21,152","shares_owned_after":36614.0,"shares_owned_after_display":"36,614","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-02","scope":"insider"},{"id":6976684,"accession":"0001209191-22-005084","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-005084","line_url":"/filing/0001209191-22-005084#line-1","is_derivative":false,"issuer_cik":"0001438533","issuer_name":"Travere Therapeutics, Inc.","issuer_ticker":"TVTX","issuer_name_source":null,"issuer_url":"/issuer/0001438533","owner_cik":"0001882909","owner_name":"Calvin Sandra","owner_display_name":"Calvin Sandra","owner_url":"/insider/0001882909","role":"Officer (VP, Corp Controller and CAO)","role_mark":"O","role_mark_label":"Officer (VP, Corp Controller and CAO)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Corp Controller and CAO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":934.0,"shares_display":"934","price_per_share":24.5767,"price_display":"24.58","price_state":"stated","total_value":22954.6378,"total_display":"22,954.64","total_whole":"22,955","shares_owned_after":28662.0,"shares_owned_after_display":"28,662","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-24","filed_date":"2022-01-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":27,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":27,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":27},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001438533","name":"Travere Therapeutics, Inc.","url":"/issuer/0001438533","role":"Officer (SVP, CHIEF ACCOUNTING OFFICER)","n_filings":19,"first_seen":"2022-01-26","last_seen":"2026-04-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001882909","retrieved_at":"2026-08-22T21:16:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}